Inflammatory panel cytokines are elevated in the neocortex of late-stage Alzheimer’s disease but not Lewy body dementias

Table 1 Detectable concentration range of measured inflammatory markers

Inflammatory marker	Detectable concentration range, Minimum–maximum (in pg/mL)
Inflammatory marker	BA21, max n = 75	BA9, max n = 74	BA40, max n = 113
IL-1α	1.0–615.0, n = 75	1.9–74.1, n = 62	1.5–45.4, n = 87
IFN-γ	0.9–277.1, n = 75	1.5–61.0, n = 69	0.6–41.2, n = 113
GM-CSF	0.8–210.0, n = 75	1.7–38.5, n = 59	0.9–3.6, n = 57
IL-13	2.3–205.0, n = 75	2.5–155.6, n = 74	0.7–59.3, n = 112
IL-10	0.3–48.9, n = 75	2.2–54.8, n = 46	1.7–176.1, n = 107
IL-1Ra	1.2–12.1, n = 75	n.a	n.a
IL-8	0.3–24.7, n = 72	n.a	n.a
IL-12p70	0.8–210.7, n = 75	n.a	n.a
FGF-2	935.6–9394.4, n = 75	n.a	n.a

BA9: Brodmann area 9 (dorsolateral/medial prefrontal cortex); BA21: Brodmann area 21 (mid-temporal gyrus); BA40: Brodmann area 40 (parietal supramarginal gyrus); FGF-2: Fibroblast growth factor 2; GM-CSF: Granulocyte–macrophage colony-stimulating factor; IFN-γ: Interferon gamma; IL: interleukin; n: number of measurements within detectable range; n.a.: not applicable. Due to limited tissue availability, our study is focused on BA21. Only markers which were significantly altered in BA21 were repeated for BA9 and BA40 to determine whether similar trends apply for different brain regions

ISSN: 1742-2094